Matches in Nanopublications for { ?s ?p "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- assertion description "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1293934.RAdh7rwkGruU7OL9Nvm8gVKgRHtK6ddkZcJbTcmscnPxI130_assertion description "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293934.RAdh7rwkGruU7OL9Nvm8gVKgRHtK6ddkZcJbTcmscnPxI130_provenance.
- NP1293944.RAcfSNAyxhciMuCucMnO409CWCf7_Mh2TohPVP8MEpm5M130_assertion description "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293944.RAcfSNAyxhciMuCucMnO409CWCf7_Mh2TohPVP8MEpm5M130_provenance.
- NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_assertion description "[First-line treatment in low-risk PV is phlebotomy to achieve a hematocrit target of 45% and low-dose aspirin, and first-line treatment in ET is observation alone in the absence of additional risk factors for arterial thrombosis (ie, JAK2 mutation and cardiovascular risk factors) or low-dose aspirin therapy, once or twice daily, in the presence of one or both of these risk factors, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293942.RAokPlllZWGRHiWxYmzo8q_vGzuhNkU40XX0dczqxsKRM130_provenance.